| Species |
Cynomolgus |
| Protein Construction |
MSLN/Mesothelin (Asp296-Gly580)
Accession # XP_005590873.4 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Immobilized MSLN/Mesothelin(296-580), His, Cynomolgus(Cat.No.: Z03872) at 1 μg/ml (100μl/Well) on the plate can bind Anti-MSLN Antibody. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
33 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 35-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Mesothelin, also known as MSLN, is encoded by the MSLN gene. It encodes a precursor protein of 71 kDa that is processed to a 31 kDa shed protein called megakaryocyte potentiating factor (MPF) and a 40 kDa fragment, mesothelin. MSLN is attached to the cell membrane by a glycosyl-phosphatidylinositol (GPI) anchor. It is a differentiation antigen which is highly expressed in several human cancers, including virtually all mesotheliomas and pancreatic adenocarcinomas. |
| Synonyms |
MSLN; CAK1; Mesothelin; MPF; MPFSMRP; SMR |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
